Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense Capecitabine in Colorectal Cancer
NCT07215936Phase 2Active, not recruiting
- Sponsor
- Sohag University
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in colorectal cancer (CRC), sponsored by Sohag University. Started Sep 2025; status: active, not recruiting.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07215936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215936.